CartiHeal enrolled the 200th patient in the Agili-C Investigational Device Exemption pivotal clinical study, up from 150 reported in 1Q19. The 200th patient was randomized to the Agili-C arm of the study and treated with three implants.
The goal of the study is to demonstrate superiority of the Agili-C implant vs. microfracture and debridement, the current surgical standard of care, for treatment of a wide range of cartilage lesions. A minimum of 250 subjects are expected, and enrollment is slated for completion in coming months.
Agili-C is a porous, biocompatible and resorbable bi-phasic aragonite-based scaffold made of interconnected natural inorganic calcium carbonate, developed to treat cartilage and osteochondral defects.
CartiHeal enrolled the 200th patient in the Agili-C Investigational Device Exemption pivotal clinical study, up from 150 reported in 1Q19. The 200th patient was randomized to the Agili-C arm of the study and treated with three implants.
The goal of the study is to demonstrate superiority of the Agili-C implant vs. microfracture and...
CartiHeal enrolled the 200th patient in the Agili-C Investigational Device Exemption pivotal clinical study, up from 150 reported in 1Q19. The 200th patient was randomized to the Agili-C arm of the study and treated with three implants.
The goal of the study is to demonstrate superiority of the Agili-C implant vs. microfracture and debridement, the current surgical standard of care, for treatment of a wide range of cartilage lesions. A minimum of 250 subjects are expected, and enrollment is slated for completion in coming months.
Agili-C is a porous, biocompatible and resorbable bi-phasic aragonite-based scaffold made of interconnected natural inorganic calcium carbonate, developed to treat cartilage and osteochondral defects.
Copy to clipboard 
